China Universal Asset Management Co. Ltd. Purchases 7,237 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

China Universal Asset Management Co. Ltd. grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 65.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,342 shares of the biotechnology company's stock after purchasing an additional 7,237 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Sarepta Therapeutics were worth $2,291,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in SRPT. Riggs Asset Managment Co. Inc. raised its stake in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company's stock valued at $774,000 after purchasing an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Sarepta Therapeutics by 1.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company's stock worth $1,000,000 after purchasing an additional 120 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Sarepta Therapeutics by 16.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company's stock worth $134,000 after buying an additional 155 shares during the last quarter. Finally, Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at about $31,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Michael Andrew Chambers bought 37,038 shares of the company's stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Down 0.0 %

Shares of Sarepta Therapeutics stock traded down $0.05 during midday trading on Tuesday, hitting $130.21. The company's stock had a trading volume of 431,584 shares, compared to its average volume of 1,235,937. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $12.31 billion, a P/E ratio of 1,184.18 and a beta of 0.82. The stock has a 50-day simple moving average of $128.59 and a 200-day simple moving average of $132.56. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter last year, the business posted ($0.27) EPS. The company's revenue for the quarter was up 38.9% on a year-over-year basis. As a group, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on SRPT. Barclays cut their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. William Blair raised Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Jefferies Financial Group began coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a "buy" rating and a $165.00 price objective on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $182.95.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.